MDLNEarnings Release财报快讯SEC sourceSEC 来源Source link原始来源August 5, 20262026/8/5by InvestLog AIInvestLog AI 整理

MDLN earnings release — EPS beat +55.2%Medline Inc. (MDLN) 财报发布 — EPS 高于预期+55.2%

Key Results

Actual vs Consensus

EPS: $0.50 vs $0.32 estimate, beat+55.2%.

Profitability and Cash Flow

Period: 2026 Q2

Revenue: $7.7B; YoY: +11.6%

Gross profit: $2.2B; Gross margin: 28.8%

Operating income: $395M; Operating margin: 5.1%; YoY: -38.5%

Net income: $60M; GAAP diluted EPS: $0.07; YoY: -82.0%

Forward Guidance

FY2026 organic-sales growth raised to 9.0–10.0% (previously 8.5–9.5%); adjusted EBITDA cut to $3.3–3.4B (previously $3.5–3.6B), mainly on inflation, operating investment, quality remediation and retail-channel softness.

Official release: Reports Second Quarter and First Six Months 2026 Results

核心结果

实际值与市场预期

EPS：$0.50 vs $0.32 预期，高于预期+55.2%。

财务指标

期间：2026 Q2

营收：$7.7B；同比：+11.6%

毛利润：$2.2B；毛利率：28.8%

经营利润：$395M；经营利润率：5.1%；同比：-38.5%

净利润：$60M；GAAP 稀释 EPS：$0.07；同比：-82.0%

前瞻指引

2026 年有机销售增长指引上调至 9.0%–10.0%（此前为 8.5%–9.5%）；调整后 EBITDA 指引下调至 33–34 亿美元（此前为 35–36 亿美元），主要受通胀压力、运营投入、质量整改和零售渠道疲软影响。

View MDLN stock details ->查看 MDLN 个股详情 ->

This earnings research was prepared from company results, regulatory filings, and financial statements. It is for informational purposes only and does not constitute investment advice.这篇财报研究基于公司业绩公告、监管文件和财务报表整理。内容仅供参考，不构成投资建议。